Research notes
Metabolic research
October 24, 2026 · 3 min read
Retatrutide: what the published phase 2 research shows about a triple-agonist peptide
A research overview of retatrutide, an investigational GIP, GLP-1 and glucagon receptor agonist, and what its published phase 2 trials reported.
Retatrutide · Metabolic research
October 21, 2026 · 2 min read
Tirzepatide: a research overview of the GIP and GLP-1 dual agonist
How tirzepatide acts on two incretin receptors, and what the SURMOUNT-1 phase 3 trial and later reviews report about it.
Tirzepatide · Metabolic research
October 17, 2026 · 2 min read
Cagrilintide and CagriSema: an amylin analogue studied alongside semaglutide
What cagrilintide is, why researchers pair an amylin analogue with a GLP-1 agonist, and what the REDEFINE 1 phase 3 trial reported.
Cagrilintide · Metabolic research
September 23, 2026 · 2 min read
AOD-9604: the growth hormone fragment studied for lipolytic activity
A review of preclinical research on AOD-9604, a modified fragment of human growth hormone, including its effects in obese rodents and how it is detected.
AOD-9604 · Metabolic research
September 19, 2026 · 2 min read
SLU-PP-332: an ERR agonist studied as an exercise mimetic
SLU-PP-332 is a synthetic small molecule, not a peptide, that activates estrogen-related receptors. Here is what the mouse studies report.
SLU-PP-332 · Metabolic research
September 2, 2026 · 2 min read
Semaglutide: what the STEP 1 trial and its follow-ups reported
A research overview of semaglutide 2.4 mg, the GLP-1 receptor agonist, based on the STEP 1 randomized trial and later work on maintenance and withdrawal.
Semaglutide · Metabolic research